UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004714
Receipt number R000005602
Scientific Title Phase I clinical study with 5 peptides vaccination in HLA-A2402-positive advanced-stage esophageal cancer patients
Date of disclosure of the study information 2010/12/14
Last modified on 2012/06/14 18:06:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase I clinical study with 5 peptides vaccination in HLA-A2402-positive advanced-stage esophageal cancer patients

Acronym

Clinical study with multi-peptides vaccination in esophageal cancer patients

Scientific Title

Phase I clinical study with 5 peptides vaccination in HLA-A2402-positive advanced-stage esophageal cancer patients

Scientific Title:Acronym

Clinical study with multi-peptides vaccination in esophageal cancer patients

Region

Japan


Condition

Condition

chemotherapy-resistance unresectable esophageal cancer

Classification by specialty

Gastroenterology Surgery in general Gastrointestinal surgery
Adult

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

safety

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

safety

Key secondary outcomes

immunological responce
tumor regression
survival time


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Vaccine

Interventions/Control_1

URLC10,TTK,KOC1,VEGFR1,VEGFR2-derived peptide vaccine

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

1)pathologicaly diagnosed esophagal squamous cell carcinoma
2)unresectable and refractory for standard chemotherapy
3)Performance status(ECOG) 0,1,2
4)obtains lesionthat can be evaluated by RECIST
5)more than 4 weeks after prior therapy
6)WBC >=2000, <=15000
Platelet>=50000
Total Bilirubin<=3.3
Creatinine<=2.2
7)HLA-A*24:02
8)obtains writen informed consent

Key exclusion criteria

1)severe comorbidity(cardiovascular disease, respiratory disease, infectious disease)
2)pregnant woman
3)systemic administration of immunosuppressant

Target sample size

9


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Soji Ozawa

Organization

Tokai University School of Medicine

Division name

Department of Gastroenterological Surgery

Zip code


Address

143 Shimokasuya, Isehara, Kanagawa, Japan

TEL

0463-93-1121

Email



Public contact

Name of contact person

1st name
Middle name
Last name Minoru Nakui

Organization

Tokai University School of Medicine

Division name

Department of Gastroenterological Surgery

Zip code


Address

143 Shimoksuya, Isehara, Kanagawa, Japan

TEL

0463-93-1121

Homepage URL

http://eso-ges.med.u-tokai.ac.jp/index.html

Email

nakui@is.icc.u-tokai.ac.jp


Sponsor or person

Institute

Tokai University school of medicine

Institute

Department

Personal name



Funding Source

Organization

Research and Study Program of Tokai University Educational System General Research Organization
2009 Tokai University School of Medicine Research Aid

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東海大学医学部付属病院(神奈川県)


Other administrative information

Date of disclosure of the study information

2010 Year 12 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 10 Month 27 Day

Date of IRB


Anticipated trial start date

2008 Year 12 Month 01 Day

Last follow-up date


Date of closure to data entry

2011 Year 11 Month 01 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 12 Month 13 Day

Last modified on

2012 Year 06 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005602


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name